Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2020 Dec 30

PMID 33375165

Citations 3

Authors

Jiri Baloun

Tereza Kropackova

Hana Hulejova

Michal Tomcik

Olga Ruzickova

Olga Sleglova

Jindriska Gatterova

Jiri Vencovsky

Karel Pavelka

Ladislav Senolt

Affiliations

Soon will be listed here.

Abstract

Background: The development of hand osteoarthritis (HOA) and its progression into the erosive subset are unclear, but inflammation is suspected to be the main source. To verify the involvement of inflammation in HOA pathogenesis, we evaluate serum inflammatory mediators and their association with HOA-related clinical features in patients.

Methods: 153 participants (50 non-erosive HOA patients, 54 erosive HOA patients, and 49 healthy control subjects) were included in this study. All patients underwent clinical examination, which included assessment of tender and swollen small hand joints, ultrasound (US) examination, and self-reported measures (e.g., AUSCAN or algofunctional indexes). Serum inflammatory mediators were quantified using human cytokine 27-plex immunoassay. We employed linear modelling, correlation analysis, and resampling statistics to evaluate the association of these mediators to HOA.

Results: We identified increased levels of nine inflammatory mediators (e.g., eotaxin, monocyte chemoattractant protein 1, interleukin-8, and tumour necrosis factor) in HOA patients compared to healthy controls. Increased mediators correlated with ultrasound findings as well as with clinically tender and swollen joint counts in patients with erosive HOA. However, none of the mediators distinguished between erosive and non-erosive HOA subtypes.

Conclusion: Our findings support the hypothesis on the involvement of inflammation in HOA.

Citing Articles

Associations of inflammatory and metabolic biomarkers with incident erosive hand osteoarthritis in the osteoarthritis initiative cohort.

McAlindon T, Hunnicutt J, Roberts M, Haugen I, Schaefer L, Driban J Osteoarthritis Cartilage. 2024; 32(5):592-600.

PMID: 38311107 PMC: 11031286. DOI: 10.1016/j.joca.2023.10.011.

Genetically predicted circulating levels of cytokines and the risk of osteoarthritis: A mendelian randomization study.

Su D, Ai Y, Zhu G, Yang Y, Ma P Front Genet. 2023; 14:1131198.

PMID: 36999058 PMC: 10043178. DOI: 10.3389/fgene.2023.1131198.

The Effects of 21-Day General Rehabilitation after Hip or Knee Surgical Implantation on Plasma Levels of Selected Interleukins, VEGF, TNF-α, PDGF-BB, and Eotaxin-1.

Idzik M, Poloczek J, Skrzep-Poloczek B, Drozdz E, Chelmecka E, Czuba Z Biomolecules. 2022; 12(5).

PMID: 35625533 PMC: 9139046. DOI: 10.3390/biom12050605.

References

Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L . Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine. 2007; 38(3):151-6. DOI: 10.1016/j.cyto.2007.06.001. View

Nees T, Rosshirt N, Zhang J, Reiner T, Sorbi R, Tripel E . Synovial Cytokines Significantly Correlate with Osteoarthritis-Related Knee Pain and Disability: Inflammatory Mediators of Potential Clinical Relevance. J Clin Med. 2019; 8(9). PMC: 6780543. DOI: 10.3390/jcm8091343. View

Scanzello C . Chemokines and inflammation in osteoarthritis: Insights from patients and animal models. J Orthop Res. 2016; 35(4):735-739. PMC: 5912941. DOI: 10.1002/jor.23471. View

Berenbaum F, Griffin T, Liu-Bryan R . Review: Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheumatol. 2016; 69(1):9-21. PMC: 5341385. DOI: 10.1002/art.39842. View

Haugen I, Slatkowsky-Christensen B, Boyesen P, Sesseng S, van der Heijde D, Kvien T . MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Ann Rheum Dis. 2014; 75(1):117-23. DOI: 10.1136/annrheumdis-2014-205949. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. PMC: 6227754. DOI: 10.1016/S0140-6736(18)32279-7. View

Dolzani P, Assirelli E, Pulsatelli L, Addimanda O, Mancarella L, Peri G . Systemic inflammation and antibodies to citrullinated peptides in hand osteoarthritis. Clin Exp Rheumatol. 2011; 29(6):1006-9. View

Punzi L, Ramonda R, Oliviero F, Sfriso P, Mussap M, Plebani M . Value of C reactive protein in the assessment of erosive osteoarthritis of the hand. Ann Rheum Dis. 2005; 64(6):955-7. PMC: 1755536. DOI: 10.1136/ard.2004.029892. View

Liu S, Hsu C, Fong Y, Chuang S, Tang C . CTGF induces monocyte chemoattractant protein-1 expression to enhance monocyte migration in human synovial fibroblasts. Biochim Biophys Acta. 2013; 1833(5):1114-24. DOI: 10.1016/j.bbamcr.2012.12.014. View

10.

Baraliakos X, Gensler L, DAngelo S, Iannone F, Favalli E, de Peyrecave N . Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. Ther Adv Musculoskelet Dis. 2020; 12:1759720X20906040. PMC: 7057409. DOI: 10.1177/1759720X20906040. View

11.

van Delft M, van Beest S, Kloppenburg M, Trouw L, Ioan-Facsinay A . Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation. J Rheumatol. 2018; 46(1):101-105. DOI: 10.3899/jrheum.180256. View

12.

Kropackova T, Sleglova O, Ruzickova O, Vencovsky J, Pavelka K, Senolt L . Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskelet Disord. 2018; 19(1):264. PMC: 6064100. DOI: 10.1186/s12891-018-2179-3. View

13.

Schmid A, Neri D . Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019; 15(4):197-207. DOI: 10.1038/s41584-019-0188-8. View

14.

Funck-Brentano T, Nethander M, Moverare-Skrtic S, Richette P, Ohlsson C . Causal Factors for Knee, Hip, and Hand Osteoarthritis: A Mendelian Randomization Study in the UK Biobank. Arthritis Rheumatol. 2019; 71(10):1634-1641. PMC: 6790695. DOI: 10.1002/art.40928. View

15.

Kloppenburg M, Peterfy C, Haugen I, Kroon F, Chen S, Wang L . Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2018; 78(3):413-420. PMC: 6390132. DOI: 10.1136/annrheumdis-2018-213336. View

16.

Chow Y, Chin K . The Role of Inflammation in the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2020; 2020:8293921. PMC: 7072120. DOI: 10.1155/2020/8293921. View

17.

Houard X, Goldring M, Berenbaum F . Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis. Curr Rheumatol Rep. 2013; 15(11):375. PMC: 3989071. DOI: 10.1007/s11926-013-0375-6. View

18.

Hsu Y, Hsieh M, Liang Y, Li C, Sheu M, Chou D . Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J Cell Biochem. 2004; 93(5):929-39. DOI: 10.1002/jcb.20239. View

19.

Philp A, Davis E, Jones S . Developing anti-inflammatory therapeutics for patients with osteoarthritis. Rheumatology (Oxford). 2016; 56(6):869-881. DOI: 10.1093/rheumatology/kew278. View

20.

Giordano R, Petersen K, Andersen H, Simonsen O, Arendt-Nielsen L . Serum Inflammatory Markers in Patients With Knee Osteoarthritis: A Proteomic Approach. Clin J Pain. 2020; 36(4):229-237. DOI: 10.1097/AJP.0000000000000804. View